📰 Beigene News
Page 16 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
July 6, 2022
BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs
June 21, 2022
OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.00 A.M. ET).In the GreenValneva SE (VALN) is up over 83% at $25.21 Grove Collaborative
June 21, 2022
Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 BeiGene
June 21, 2022
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) CFO Julia Aijun Wang sold 161 shares of BeiGene stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $136.64, for a total value of $21,999.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is […]
June 14, 2022
Chinese biotech enterprise BeiGene announced on Monday that its cancer treatment Brukinsa (zanubrutinib) has been approved by authorities in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.This development means the drug has received more than 20 approvals covering 50 countries and regions, including the United States, China, the European Union, Great Britain, Canada, and Australia. Currently, more than 40 addit...
June 13, 2022
13.06.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide today announced that its BTK ... Seite 1
June 6, 2022
Equities analysts expect that BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) will report $312.21 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for BeiGene’s earnings, with the lowest sales estimate coming in at $307.52 million and the highest estimate coming in at $316.90 million. BeiGene posted sales of $149.99 million […]
June 4, 2022
Wall Street brokerages predict that BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) will post ($4.38) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for BeiGene’s earnings, with the lowest EPS estimate coming in at ($4.45) and the highest estimate coming in at ($4.30). BeiGene reported […]
May 20, 2022
Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have been given an average recommendation of “Buy” by the eight ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The […]
May 17, 2022
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new